Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy

Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic myopathy triggered by exposure to volatile anesthetics and/or depolarizing muscle relaxants. Susceptibility to ME is primarily associated with dominant mutations in the ryanodine receptor type 1 gene (RYRI). Recent genetic studies have shown that RYRI variants are the most common cause of dominant and recessive congenital myopathies central core and multi-minicore disease, congenital fiber type disproportion, and centronuclear myopathy. However, the MH status of many patients, especially with recessive RYR1-related myopathies, remains uncertain. We report the occurrence of a triplet of RYRI variants, c.4711A>G (p.Ile1571Val), c.10097G>A (p.Arg3366His), c.11798A>G (p.Tyr3933Cys), found in cis in four unrelated families, one from Belgium, one from The Netherlands and two from Canada. Phenotype genotype correlation analysis indicates that the presence of the triplet allele alone confers susceptibility to ME, and that the presence of this allele in a compound heterozygous state with the MH-associated RYRI variant c.14545G>A (p.Va14849Ile) results in the MH susceptibility phenotype and a congenital myopathy with cores and rods. Our study underlines the notion that assigning pathogenicity to individual RYR1 variants or combination of variants, and counseling in RYR1-related myopathies may require integration of clinical, histopathological, in vitro contracture testing, MRI and genetic findings. (C) 2015 Elsevier B.V. All rights reserved.